London secures major investment to accelerate healthcare innovation

pharmafile.com | November 18, 2026 | News story | |  Cardiology, Corporate, Devices, Diagnostics, Healthcare Technologies, Healthcare investment, bioinnovation, clinical, quantum 

More than £500m in financing and investment has been announced for London’s science and technology sectors, including funding intended to help translate biomedical research into commercial applications and bring healthcare innovations closer to clinical use.

The announcements, made during London Life Sciences Week, include £147m from the National Wealth Fund towards a major life sciences development at Canary Wharf and £22m from the Mayor of London for three innovation projects spanning healthcare and quantum technology.

Two of the Mayor’s funded projects have a direct healthcare focus, targeting the translation of research into new treatments, medical technologies and approaches to disease prevention.

Advertisement

A £5m investment will support a King’s College London-led partnership with the BioInnovation Institute to help turn cardiometabolic research into new businesses developing treatments and medical technologies. This includes approaches to the earlier detection of heart disease.

A further £5m will support PHIX London, led by UCLPartners in collaboration with NHS and private healthcare providers in the Harley Street Health District. The initiative will give businesses opportunities to test and scale healthcare technologies, including tools for detecting and monitoring high blood pressure and irregular heart rhythms.

The projects will receive more than £98m in additional match funding, including pledged contributions, taking the combined investment identified to over £120m. They form part of the Local Innovation Partnerships Fund (LIPF), a wider UK Research and Innovation programme investing up to £500m in high-potential innovation clusters across the UK.

Professor Kevin Fenton, Regional Director of Public Health, NHS London and OHID London, said: “Preventing cardiovascular disease (CVD) is one of London’s biggest public health priorities, and achieving our ambitions will require new ideas, stronger partnerships and faster adoption of proven innovations. 

“These two complementary proposals connect research, venture development, clinical testing and NHS implementation, helping promising discoveries reach the people and communities who need them most. Together, they could strengthen London’s Million Hearts and Minds prevention programme, reduce inequalities and position London as a global leader in cardiovascular innovation.”

The wider investment package also includes £147m in debt financing from the National Wealth Fund towards One North Quay at Canary Wharf. The funding forms part of a £368.5m financing package alongside Barclays and Emirates NBD, and represents the Fund’s first investment in the life sciences sector.

Being developed by CWG and Kadans Science Partner, the 23-storey building will provide around 570,000 sq ft of flexible laboratory and workspace for established businesses and growing SMEs. It is intended to address a shortage of specialist facilities for companies developing and commercialising new technologies, with completion expected in early 2028.

Oliver Holbourn, CEO of the National Wealth Fund, said the investment would help provide the specialist infrastructure needed for science and innovation businesses to start, grow and scale in the UK.

The remaining £12m of the Mayor’s funding will support the London Quantum Cluster, led by UCL, Imperial College London and King’s College London. The initiative aims to help high-growth companies test technologies, attract investment and develop applications across sectors including healthcare, transport, finance, energy and defence. Potential healthcare applications include the development of new medicines.

The announcements highlight the importance of connecting scientific research with the investment, infrastructure and commercial partnerships needed to bring new technologies into practical use. 

Max Stanyard, healthcare and life sciences senior analyst at RSM UK, said public investment could help unlock additional private capital, addressing a persistent challenge for companies seeking to commercialise and scale their technologies in the UK.

Pic: NCI

Related Content

healthcare tech

Doctors ‘distrust apps developed by pharma’ – survey

A study of GPs in three European countries show GPs feel there is a role …

News image

The numbers game: getting quantitative information to patients

The great physicist Lord Kelvin said: “If you can measure something, and express it in …

Records image

NHS patient data and clinical research – coming together at last?

In the mid-1990s, an NHS teaching hospital close to my offices invited proposals for expanding …

The Gateway to Local Adoption Series

Latest content